The Petri Dish: Boston biotech scores FDA approval, antiviral maker stops 3 studies
Chiesi Global Rare Diseases, a Boston-based business unit of Italian biopharma firm Chiesi Group, scored an approval from the U.S. Food and Drug Administration for a skin disorder drug. Plus, other life sciences news you may have missed.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Rowan Walrath Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Health Management | Italy Health | Rare Diseases | Skin | Study